Bevacizumab is an important kind of remedy for metastatic colon cancer, which belongs to humanized anti-VEGF monoclonal antibody. Approved by FDA, bevacizumab came into the market in 2004, with the brand name of \"Avastin\". Its main mechanism is to inhibit the function of a natural protein called vascular endothelial growth factor (VEGF) that stimulates new blood vessel formation through specific binding so as to stop or delay growth of blood vessels in tumor, disconnect the delivery of oxygen and other nutrition necessary in tumor cells\' growth, as well as to improve the effect of chemotherapy remedy. Public data shows that the global sales value of bevacizumab in 2012 exceeded USD 6.3 billion, ranking the fourth among the 10 best selling monoclonal antibody drugs.
As Chinese economy develops rapidly, Chinese people\'s lifestyle is changing tremendously. With the aging level increasing, environment pollution worsening, the incidence of cancer in China keeps rising. Statistics indicate that the annual increase of cancer patients in China takes up over 20% of the global, making China a capital antitumor remedy market of the world. Shanghai Roche Pharmaceuticals Ltd. declared on May 7, 2010 that its bevacizumab injection (brand name \"Avastin\") was approved by the FDA for curing metastatic colorectal cancer. It is the official entry of the world\'s first angiogenesis inhibitor into Chinese market. The market investigation of CRI manifests that the sales value of Avastin in certain Chinese sample hospitals in 2010 was merely CNY 10 million, growing rapidly. It broke through CNY 200 million in 2013.
There have been some generic drug manufacturers developing bevacizumab around the world. At the end of 2013, Huahai Pharmaceutical in China announced that its bevacizumab generic drug developed with Oncobiologics Company was approved to conduct the first clinical trial in the European Union.
Some study declared that the combination of bevacizumab and chemotherapy can prolong overall survival time of advanced cervical cancer patients. This result indicates the possibility of this remedy with the annual sales value of USD 1 billion to treat cervical cancer.
Through this report, the readers can acquire the following information:
- Market Share of Major Bevacizumab Manufacturers in Sample Hospitals in China
- Sales price of Bevacizumab in Hospital Market in China
- Share of Bevacizumab in Different Dosage Forms in Hospital Market in China
- Incidence of Cancer in China
- Manufacturing Schedule of Bevacizumab generic drug
- Prospect of China Bevacizumab Market
Table of Content
1 Relevant Concepts of Bevacizumab
1.2 Sales Status on the Global Market
2 Market Overview of Bevacizumab in China, 2010-2013
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size
3 Investigation on Sales Value of Bevacizumab in China, 2010-2013
3.1 Total Sales Value
3.2 Sales Value by Region
4 Investigation on Market Share of Major Bevacizumab Manufacturers in China, 2010-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 Investigation on Market Size of Bevacizumab by Dosage Form in China, 2010-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form
6 Reference Price of Bevacizumab in Hospital Market in China, 2010-2013
6.1 Shanghai Roche Pharmaceuticals Ltd.
7 Prospect of China Bevacizumab Market, 2014-2018
7.1 Forecast on Incidence of Cancer
7.2 Forecast on Market Size
7.3 Forecast on Competition Pattern
List of Chart
Chart Bevacizumab Products Approved to Market in China, 2014
Chart Forecast on Market Size of Hospital-use Bevacizumab in China, 2014-2018
Chart Global Sales Value of Bevacizumab, 2010-2013
Chart Sales Value of Bevacizumab in Hospital Market in China, 2010-2013
Chart Sales Value of Bevacizumab by Region in China, 2010-2013
Chart Market Share of Bevacizumab Enterprises by Sales Value in China, 2010-2013
Chart Price of Bevacizumab Produced by GENENTECH(US) in Hospital Market
Chart Price of Bevacizumab Produced by Shanghai Roche in Hospital Market, 2010-2013
Make an enquiry before buying this Report
Please fill the enquiry form below.